Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Seaport Research raised the firm’s price target on Hims & Hers to $32 from $28 and keeps a Buy rating on the shares. The company ...

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Hims stock rose early Tuesday after compounded weight-loss drugs helped build on a "robust" trajectory for Hims & Hers Health ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

Headlines,Hims & Hers Health Surpasses Earnings Expectations,Strong Revenue Growth Drives Positive Stock Movement,Analysts ...

Tropical Storm Rafael, which is expected to strengthen and may hit the Gulf Coast later this week, could further disrupt the IV solution supply chain if its path shifts towards Texas, where 4.4% of U.